LVZP.F Stock Overview
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.28 |
| 52 Week High | CN¥3.63 |
| 52 Week Low | CN¥3.20 |
| Beta | 0.28 |
| 11 Month Change | -9.64% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -6.82% |
| 5 Year Change | n/a |
| Change since IPO | -29.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LVZP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.6% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how LVZP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LVZP.F performed against the US Market.
Price Volatility
| LVZP.F volatility | |
|---|---|
| LVZP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LVZP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LVZP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 8,920 | Yanggang Tang | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| LVZP.F fundamental statistics | |
|---|---|
| Market cap | US$4.11b |
| Earnings (TTM) | US$279.42m |
| Revenue (TTM) | US$1.64b |
16.6x
P/E Ratio2.8x
P/S RatioIs LVZP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVZP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥11.86b |
| Cost of Revenue | CN¥4.39b |
| Gross Profit | CN¥7.46b |
| Other Expenses | CN¥5.44b |
| Earnings | CN¥2.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.22 |
| Gross Margin | 62.94% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 27.4% |
How did LVZP.F perform over the long term?
See historical performance and comparison